Trametinib impact on in vitro naive and effector T-cell viability and proliferation response. CFSE-labeled CD3⁺ cells from wild-type and AML mice after a 3-day in vitro proliferation assay. (A-B) Summary of the percentage of Zombie Aqua negative, or alive, CD3⁺ cells from AML (n = 3) and wild-type (n = 3) mice from 3 independent experiments. (C-D) Representative flow cytometry plots gated on CD3⁺CD8⁺ cells showing proliferation for subpopulations divided by CD44 or CD62L expression for cells from an AML mouse and a wild-type mouse treated in vitro with no stimulation, anti-CD3 stimulation, or anti-CD3 stimulation plus trametinib 10 nM. (E-F) Mean ± SD population percentages for expression of CD44 and/or CD62L for CD3⁺CD8⁺ cells from AML mice (n = 3) or wild-type mice (n = 3). (G-H) Mean ± SD percentage of dividing CD3⁺CD8⁺ T cells from AML (n = 3) and wild-type mice (n = 3) divided by expression of CD44 and/or CD62L and treatment condition. Displaying Tukey pairwise comparisons between treatment conditions (A-B), Tukey pairwise comparison for unstimulated vs all other treatment conditions (G-H). (A-B,G-H) Statistically significant results displayed as: *P < .05; **P < .01.